Indaptus Therapeutics Competitors and Similar CompaniesClear all
Indaptus Therapeutics's competitors and similar companies include Seagen, Mallinckrodt Pharmaceuticals, Opsy and OnCusp Therapeutics.
 Indaptus Therapeutics Indaptus Therapeutics. is a biopharmaceutical company that specializes in cancer and other infectious disease treatment solutions. |  Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. |  Mallinckrodt Pharmaceuticals Mallinckrodt is a business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies. |  Opsy Opsy Holding (formerly WntResearch) is a biotech company that develops therapies for preventing cancer spread. |  OnCusp Therapeutics OnCusp Therapeutics is a biopharmaceutical company that specializes in cancer treatment solutions. | |
Founding Date | Founding Date 2021 | Founding Date 1998 | Founding Date 1867 | Founding Date 2007 | Founding Date 2021 |
Type | Type Public | Type Subsidiary | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations HQ | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more | Locations Dublin 15, IE HQ Staines, GB Hazelwood, US Webster Groves, US | Locations Gothenburg, SE HQ Lund, SE | Locations New York, US HQ Shanghai, CN Shanghai, CN |
Employees | Employees N/A | Employees 3,25622% increase | Employees 3,373 | Employees 2 | Employees 2519% increase |
Valuation ($) | Valuation ($) 12.6 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 721.5 k | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $2b (FY, 2022) | Revenue (est.) $1b (FY, 2022) | Revenue (est.) kr6.7m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $410.1m (FY, 2022) | Cost of goods $643.5m (FY, 2022) | Cost of goods kr1.3m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $1.6b (FY, 2022) | Gross profit $396.2m (FY, 2022) | Gross profit kr5.4m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income ($610.3m) (FY, 2022) | Net income ($598.3m) (FY, 2022) | Net income (kr17.2m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 164m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 125m |
For sources of this data, please see the company profile
View Company Profiles
Seagen
HQ
Bothell, US
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
View companyMallinckrodt Pharmaceuticals
HQ
Dublin 15, IE
Employees
3,373
Mallinckrodt is a business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies.
View companyOpsy
HQ
Gothenburg, SE
Employees
2
Opsy Holding (formerly WntResearch) is a biotech company that develops therapies for preventing cancer spread.
View companyOnCusp Therapeutics
HQ
New York, US
Employees
25↑ 19% increase
OnCusp Therapeutics is a biopharmaceutical company that specializes in cancer treatment solutions.
View company